Development of the proteasome inhibitor Velcade™ (Bortezomib)

Cancer Investigation

Volumn 22, Issue 2, 2004, Pages 304-311

  Adams, Julian ^a,b   Kauffman, Michael ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Infinity Pharmaceuticals Inc   (United States)

Author keywords

Antineoplastic agents; Boronic acids; Enzyme inhibitors (administration and dose); Hematologic neoplasms (drug therapy); Multienzyme complexes (antagonists and inhibitors); NF B (antagonists and inhibitors)

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CEP 1612; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN BETA LACTONE; MLM 341; MULTIENZYME COMPLEX; PROTEASOME; PROTEASOME INHIBITOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYELOMA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

BORONIC ACIDS; CELL SURVIVAL; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN-ACTIVATING ENZYMES;

EID: 2642551603     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120030218     Document Type: Review

References (52)

1. Adams, J.; Palombella, V.J.; Sausville, E.A.; Johnson, J.; Destree, A.; Lazarus, D.D.; Maas, J.; Pien, C.S.; Prakash, S.; Elliott, P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59, 2615-2622.
2. Bold, R.J.; Virudachalam, S.; McConkey, D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001, 100, 11-17.
3. Cusack, J.C., Jr.; Liu, R.; Houston, M.; Abendroth, K.; Elliott, P.J.; Adams, J.; Baldwin, A.S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001, 61, 3535-3540.
4. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071306-3071307.
5. Shah, S.A.; Potter, M.W.; McDade, T.P.; Ricciardi, R.; Perugini, R.A.; Elliott, P.J.; Adams, J.; Callery, M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 2001, 82, 110-122.
6. Logothetis, C.J.; Yang, H.; Daliani, D.; Millikan, R.E.; Tu, S.; Pagliaro, L.; Adams, J.; Elliott, P.; Nix, D.; Dieringer, P.; Papandreou, C.N. Dose-dependent inhibition of 20S proteasome results in serum Il-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. 2001, 20, 186a.
7. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H.D. ; Huber, R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997, 386, 463-471.
8. Lowe, J.; Stock, D.; Jap, B.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 1995, 268, 53353-53359.
9. Stock, D.; Ditzel, L.; Baumeister, W.; Huber, R.; Lowe, J. Catalytic mechanism of the 20S proteasome of thermoplasma acidophilum revealed by x-ray crystallography. Cold Spring Harbor Symp. Quant. Biol. 1995, 60, 525-532.
10. Nussbaum, A.K.; Dick, T.P.; Keilholz, W.; Schirle, M.; Stevanovic, S.; Dietz, K.; Heinemeyer, W.; Groll, M.; Wolf, D.H.; Huber, R.; Rammensee, H.G.; Schild, H. Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 12504-12509.
11. Adams, J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7, 9-16.
12. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.T.; Plamondon, L.; Stein, R.L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 1998, 8, 33333-33338.
13. Dietrich, C.; Bartsch, T.; Schanz, F.; Oesch, F.; Wieser, R.J. p53-Dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L- leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 10815-10819.
14. An, W.G.; Hwang, S.G.; Trepel, J.B.; Blagosklonny, M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14, 1276-1283.
15. Wu, Y.; Luo, H.; Kanaan, N.; Wu, J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J. Cell. Biochem. 2000, 76, 596-604.
16. Dulic, V.; Kaufmann, W.K.; Wilson, S.J.; Tlsty, T.D.; Lees, E.; Harper, J.W.; Elledge, S.J.; Reed, S.I. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76, 1013-1023.
17. King, R.W.; Deshaies, R.J.; Peters, J.M.; Kirschner, M.W. How proteolysis drives the cell cycle. Science 1996, 274, 1652-1659.
18. Pagano, M.; Tam, S.W.; Theodoras, A.M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P.R.; Draetta, G.F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685.
19. Desai, S.D.; Liu, L.F.; Vazquez-Abad, D.; D'Arpa, P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 1997, 272, 24159-24164.
20. Ogiso, Y.; Tomida, A.; Lei, S.; Omura, S.; Tsuruo, T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase Il-directed drugs. Cancer Res. 2000, 60, 2429-2434.
21. Adams, J.; Palombella, V.J.; Elliott, P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 2000, 18 (2), 109-121.
22. Drexler, H.C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 855-860.
23. Masdehors, P.; Omura, S.; Merle-Beral, H.; Mentz, F.; Cosset, J.M.; Dumont, J.; Magdelenat, H.; Delic, J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 1999, 105, 752-757.
24. An, B.; Goldfarb, R.H.; Siman, R.; Dou, Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5, 1062-1075.
25. Kordes, U.; Krappmann, D.; Heissmeyer, V.; Ludwig, W.D.; Scheidereit, C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000, 14, 399-402.
26. Tricot, G. New insights into role of microenvironment in multiple myeloma. Lancet 2000, 355, 248-250.
27. Patel, N.M.; Nozaki, S.; Shortle, N.H.; Bhat-Nakshatri, P.; Newton, T.R. ; Rice, S.; Gelfanov, V.; Boswell, S.H.; Goulet, R.J., Jr.; Sledge, G.W., Jr.; Nakshatri, H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 1999, 19, 4159-4169.
28. Jeremias, I.; Kupatt, C.; Baumann, B.; Herr, I.; Wirth, T.; Debatin, K.M. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998, 91, 4624-4631.
29. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 2001, 107, 241-246.
30. Scherer, D.C.; Brockman, J.A.; Chen, Z.; Maniatis, T.; Ballard, D.W. Signal-induced degradation of IκBα requires site-specific ubiquitination. Proc. Nall. Acad. Sci. U. S. A. 1995, 92, 11259-11263.
31. Spencer, E.; Jiang, J.; Chen, Z.J. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 1999, 13, 284-294.
32. Winston, J.T.; Strack, P.; Beer-Romero, P.; Chu, C.Y.; Elledge, S.J.; Harper, J.W. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IKBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 1999, 13, 270-283.
33. Alkalay, I.; Yaron, A.; Hatzubai, A.; Orian, A.; Ciechanover, A.; Ben-Neriah, Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 10599-10603.
34. Baldi, L.; Brown, K.; Franzoso, G.; Siebenlist, U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκB-α. J. Biol. Chem. 1996, 271, 376-379.
35. Chen, Z.; Hagler, J.; Palombella, V.J.; Melandri, F.; Scherer, D.; Ballard, D.; Maniatis, T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 1995, 9, 1586-1597.
36. Lin, Y.C.; Brown, K.; Siebenlist, U. Activation of NF-κB requires proteolysis of the inhibitor IκB-α: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 526-552.
37. Roff, M.; Thompson, J.; Rodriguez, M.S.; Jacque, J.M.; Baleux, F.; Arenzana-Seisdedos, F.; Hay, R.T. Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo. J. Biol. Chem. 1996, 271, 7844-7850.
38. Chen, C.; Edelstein, L.C.; Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 2000, 20, 2687-2695.
39. Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S., Jr. NF-κB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation. Science 1998, 281, 1680-1683.
40. Wang, C.Y.; Guttridge, D.C.; Mayo, M.W.; Baldwin, A.S., Jr. NF-κB induces expression of the Bcl-2 homologue Al/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999, 19, 5923-5929.
41. Zong, W.X.; Edelstein, L.C.; Chen, C.; Bash, J.; Gelinas, C. The prosurvival Bcl-2 homolog Bfl-1/ A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1999, 13, 382-387.
42. Russo, S.M.; Tepper, J.E.; Baldwin, A.S., Jr.; Liu, R.; Adams, J.; Elliott, P.; Cusack, J.C., Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 183-193.
43. LeBlanc, R.; Catley, L.; Hideshima, T.; Pien, C.S.; Elliott, P.J.; Anderson, K.C. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood 2001, 98 (11).
44. Pham, L.; Tamayo, A.; Lo, P.; Yoshimura, L.; Ford, R.J. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001, 98 (11).
45. Ma, M.H.; Parker, K.M.; Manyak, S.; Altamirano, C.V.; Wu, Z.Q.; Borad, M.J.; Roussos, E.; Neeser, J.; Mikail, A.; Frantzen, M.; Adams, J.; Yang, H.; Sjak-Shie, N.; Vescio, R.A.; Berenson, J.R. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood 2001, 98 (11).
46. Feinman, R.; Aris, V.M.; Vergano, S.; Galante, A.T.; Soteropoulos, P.; Gangurde, P.; Siegel, D.S.; Adams, J.; Elliott, P.J.; Tolias, P.P. Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone arsenic trioxide, and PS-341. Blood 2001, 98 (11).
47. Steiner, P.; Neumeier, H.; Lightcap, E.; Sadis, S.; Pien, C.; Pink, M.; Lesoon, A.; Rolfe, M.; Elliott, P.; Adams, J.; Bolen, J.; Read, M. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 2001, 98 (11).
48. Nix, D.; Pien, C.; Newman, R.; Madden, T.; Felix, E.; Adams, J.; Elliott, P. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc. Am. Soc. Clin. Oncol. 2001, 20, 86a.
49. Lightcap, E.S.; McCormack, T.A.; Pien, C.S.; Chau, V.; Adams, J.; Elliott, P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 2000, 46, 673-683.
50. Adams, J. Proteasome inhibition in cancer: development of PS-341. Sem. Oncol. 2001, 28 (6), 613-619.
51. Papandreou, C.; Daliani, D.; Millikan, R.E.; Tu, S.; Pagliaro, L.; Adams, J.; Elliott, P.; Nix, D.; Dieringer, P.; Thall, P.; Logothetis, C.J. Phase I study of IV proteasome inhibitor PS-341 in patients (pts) with advanced malignancies. Proc. Am. Soc. Oncol. 2001, 20, 86a.
52. Richardson, P.; Berenson, J.; Irwin, D.; Jagannath, S.; Singhal, S.; Traynor, A.; Rajkumar, V.; Alsina, M.; Kuter, D.; Srkalovic, G.; Siegel, D.; Barlogie, B.; Alexanian, R.; Orlowski, R.; Esseltine, D.; Kauffman, M.; Adams, J.; Schenkein, D.P.; Anderson, K.C. Phase II study PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001, 98 (11).